GenSight Biologics S.A. (SIGHT.PA)
EUR 0.22
(-2.61%)
EUR 0.22
(-2.61%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 3 Million EUR | 16.19% |
| 2022 | 2.58 Million EUR | -51.06% |
| 2021 | 5.27 Million EUR | 20.07% |
| 2020 | 4.39 Million EUR | 527.71% |
| 2019 | 700 Thousand EUR | -82.63% |
| 2018 | 4.03 Million EUR | 15.9% |
| 2017 | 3.47 Million EUR | 24.28% |
| 2016 | 2.79 Million EUR | -18.21% |
| 2015 | 3.42 Million EUR | 210.27% |
| 2014 | 1.1 Million EUR | 21.38% |
| 2013 | 908.44 Thousand EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 864 Thousand EUR | 171.88% |
| 2024 Q2 | 864 Thousand EUR | 0.0% |
| 2023 Q3 | 124 Thousand EUR | -90.87% |
| 2023 Q1 | 1.35 Million EUR | 342.35% |
| 2023 Q4 | -1.2 Million EUR | -1069.35% |
| 2023 FY | 3 Million EUR | 16.19% |
| 2023 Q2 | 1.35 Million EUR | 0.0% |
| 2022 Q4 | 307 Thousand EUR | 0.0% |
| 2022 Q3 | 307 Thousand EUR | -85.56% |
| 2022 Q1 | 2.12 Million EUR | 413.41% |
| 2022 Q2 | 2.12 Million EUR | 0.0% |
| 2022 FY | 2.58 Million EUR | -51.06% |
| 2021 FY | 5.27 Million EUR | 20.07% |
| 2021 Q2 | 3.44 Million EUR | 0.0% |
| 2021 Q4 | 414 Thousand EUR | 0.0% |
| 2021 Q1 | 3.44 Million EUR | 65.33% |
| 2021 Q3 | 414 Thousand EUR | -87.97% |
| 2020 Q2 | 1.63 Million EUR | 0.0% |
| 2020 Q3 | 2.08 Million EUR | 26.97% |
| 2020 Q4 | 2.08 Million EUR | 0.0% |
| 2020 FY | 4.39 Million EUR | 527.71% |
| 2020 Q1 | 1.63 Million EUR | 34.12% |
| 2019 Q3 | 1.22 Million EUR | 80.24% |
| 2019 Q2 | 678 Thousand EUR | -45.01% |
| 2019 Q1 | 1.23 Million EUR | 25.24% |
| 2019 FY | 700 Thousand EUR | -82.63% |
| 2019 Q4 | 1.22 Million EUR | 0.0% |
| 2018 Q1 | 1.01 Million EUR | 18.26% |
| 2018 Q3 | 1.15 Million EUR | 32.74% |
| 2018 Q4 | 984.5 Thousand EUR | -15.09% |
| 2018 FY | 4.03 Million EUR | 15.9% |
| 2018 Q2 | 873.5 Thousand EUR | -13.81% |
| 2017 Q4 | 857 Thousand EUR | 0.0% |
| 2017 Q1 | 994 Thousand EUR | 76.4% |
| 2017 FY | 3.47 Million EUR | 24.28% |
| 2017 Q2 | 994 Thousand EUR | 0.0% |
| 2017 Q3 | 857 Thousand EUR | -13.78% |
| 2016 Q1 | 937 Thousand EUR | 6.31% |
| 2016 Q3 | 563.5 Thousand EUR | -39.86% |
| 2016 Q2 | 937 Thousand EUR | 0.0% |
| 2016 Q4 | 563.5 Thousand EUR | 0.0% |
| 2016 FY | 2.79 Million EUR | -18.21% |
| 2015 Q3 | 881.39 Thousand EUR | -1.91% |
| 2015 Q4 | 881.39 Thousand EUR | 0.0% |
| 2015 FY | 3.42 Million EUR | 210.27% |
| 2015 Q2 | 898.6 Thousand EUR | 0.0% |
| 2015 Q1 | 898.6 Thousand EUR | 338.55% |
| 2014 Q4 | 204.9 Thousand EUR | 0.0% |
| 2014 FY | 1.1 Million EUR | 21.38% |
| 2014 Q1 | 346.44 Thousand EUR | 0.0% |
| 2014 Q3 | 204.9 Thousand EUR | -40.85% |
| 2014 Q2 | 346.44 Thousand EUR | 0.0% |
| 2013 FY | 908.44 Thousand EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| ABIONYX Pharma SA | 618 Thousand EUR | -385.437% |
| ABIVAX Société Anonyme | 3.91 Million EUR | 23.352% |
| Adocia SA | 1.38 Million EUR | -116.606% |
| Aelis Farma SA | 12.35 Million EUR | 75.724% |
| Biophytis S.A. | -803 Thousand EUR | 473.599% |
| Advicenne S.A. | 1.42 Million EUR | -110.379% |
| genOway Société anonyme | 20.1 Million EUR | 85.075% |
| IntegraGen SA | 5.01 Million EUR | 40.219% |
| Medesis Pharma S.A. | -2.66 Million EUR | 212.58% |
| Neovacs S.A. | 29.31 Thousand EUR | -10134.018% |
| NFL Biosciences SA | -56.06 Thousand EUR | 5451.027% |
| Plant Advanced Technologies SA | 2.15 Million EUR | -39.346% |
| Quantum Genomics Société Anonyme | -1.41 Million EUR | 311.373% |
| Sensorion SA | 3.78 Million EUR | 20.8% |
| Theranexus Société Anonyme | -4.63 Million EUR | 164.673% |
| TME Pharma N.V. | -127 Thousand EUR | 2462.205% |
| Valbiotis SA | 2.66 Million EUR | -12.444% |
| TheraVet SA | -530.79 Thousand EUR | 665.189% |
| Valerio Therapeutics Société anonyme | 1.26 Million EUR | -136.78% |
| DBV Technologies S.A. | 4.15 Million EUR | 27.878% |
| Genfit S.A. | 28.22 Million EUR | 89.371% |
| GeNeuro SA | -293.8 Thousand EUR | 1121.103% |
| Innate Pharma S.A. | -4.12 Million EUR | 172.798% |
| Inventiva S.A. | 17.5 Million EUR | 82.857% |
| MaaT Pharma SA | 1.65 Million EUR | -81.269% |
| MedinCell S.A. | 9.28 Million EUR | 67.7% |
| Nanobiotix S.A. | 36.2 Million EUR | 91.715% |
| OSE Immunotherapeutics SA | 2.22 Million EUR | -34.71% |
| Poxel S.A. | 1000.00 EUR | -299900.0% |
| Transgene SA | -28.4 Million EUR | 110.562% |
| Valneva SE | 52.83 Million EUR | 94.322% |